Nasal natural killer cell lymphoma presenting as lethal midline granuloma.
Yamazaki
M
M
Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, Japan.
Kakuta
M
M
Takimoto
R
R
Murayama
N
N
Takamori
K
K
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D003520:Cyclophosphamide / Q000627:therapeutic use; D017931:DNA Primers / Q000737:chemistry; D004273:DNA, Neoplasm / Q000032:analysis; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000627:therapeutic use; D006103:Granuloma, Lethal Midline / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007694:Killer Cells, Natural / Q000737:chemistry / Q000187:drug effects / Q000473:pathology*; D016399:Lymphoma, T-Cell / Q000737:chemistry / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D010255:Paranasal Sinus Neoplasms / Q000737:chemistry / Q000175:diagnosis* / Q000188:drug therapy; D016133:Polymerase Chain Reaction; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D014408:Biomarkers, Tumor; D017931:DNA Primers; D004273:DNA, Neoplasm; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone